Moderna rises on study suggesting COVID-19 shot enhances efficacy of cancer treatment
Moderna rose more than 5% on Monday after a new study showed that mRNA COVID-19 shots could enhance cancer immunotherapy.
The results were presented by researchers from MD Anderson Cancer Center at the European Society for Medical Oncology conference in Berlin on Sunday, Stat News and others reported. The study found that cancer patients who took the COVID-19 shot within 100 days of taking an immunotherapy drug lived longer.
Moderna was tapped by the first Trump administration alongside Pfizer to quickly develop an immunization for Covid in 2020. Moderna still makes nearly all of its revenue from the vaccine while Pfizer has a larger, more diversified portfolio. Moderna has other products in its pipeline, including a dual flu and COVID-19 vaccine and personalized cancer vaccines.